Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07516691
Starting soon Observational

Evaluation of a New Strategy to Approach the Transgender Sex Worker Populations and Their Clients for Access to a Preventive Sexual Health System Through the ORTIF Digital Teleconsultation Solution

NCT07516691 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2026-05-01
Last updated
2026-04-08

Condition(s) studied

HIV

Study summary

The prevalence of HIV (Human Immunodeficiency Virus) and STIs (Sexually Transmitted Infections) is very high in the trans population, due to multifactorial components.

The main risk factors for HIV in this population are unprotected receptive and insertive anal intercourse, multiple sexual partners, sex work, needles share for injecting drugs and hormones.

Physical violence, sexual assault and lack of social and family support are supplementary social risk factors.

Healthcare access is very limited in this socio-economic context. The population of transgender persons and their transmission chains (partners, clients, etc.) are highly exposed to HIV risk, but they are still "hidden" populations, not targeted by prevention programs.

Innovative preventive strategies can improve sexual health services access for these specific populations.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 'For population of E-prevent telemedicine service users : * Individuals aged ≥18 years * Registered on a trans escort-client dating website or having sexual relations with trans individuals in exchange for money * Agreeing to complete at least one teleconsultation through the E-PrevenT program * Agreeing to provide a phone number and an email address for the teleconsultation * No verbal objection to participating in the study For population of trans individuals invited to collaborate in the study (seeds of the RDS strategy): * Trans or non-binary individuals aged ≥18 years * Engaged in sexual activity in exchange for money (sex work) * Commitment to complete sexual health training sessions (twice per year) * No verbal objection to participating in the study Exclusion Criteria: * Person under guardianship, curatorship or other French legal protections schemes

Primary outcome measure(s)

  • Number of trans sex workers or clients who joined the E-PrevenT system during the study period. — 2 years
    Objective is to assess the access of the transgender sex worker population and their clients to an innovative preventive sexual health program, based on the ORTIF digital teleconsultation solution.

Trial sites (1)

FacilityCityRegionStatus
Hôpital Bichat-Claude Bernard Paris Ap-hp DRCI

More Assistance Publique - Hôpitaux de Paris trials in France

Analysis of the Influence of Gastric By-Pass on the Pharmacokinetics of Common Drugs Starting soon
Electrophysiological Analysis of Gamma-Hydroxybutyrate-induced Sleep in Intensive Care Patients Starting soon
Antibioprophylaxis for Excision-graft Surgery in Burn Patient (A2B-TRIAL) Recruiting
French Cohort of Myocardial Infarction Evaluation Recruiting
Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine Recruiting

Other trials for the same condition

Quality of Life Related to the Care of Women Living With HIV During the Perinatal Period Recruiting
Quality of Care in French HIV Infected Patients Recruiting
Comparison of Inflammatory Markers and Incidence of Comorbidities in Patients on Antiretroviral Therapy With Second-generation Anti-integrase Drugs on Triple Versus Dual Therapy Active, not recruiting
EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV Enrolling by invitation
Platelets Target the Circulating HIV Reservoir: Implications for Immunological Failure Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07516691 on ClinicalTrials.gov ↗ ← All trials in France